Maasoumy B, et al. - In patients with hepatitis C virus (HCV) genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real-world cohort, researchers studied the frequency and predictive value of detectable and quantifiable HCV RNA results at the end of antiviral treatment (EOT). In this real-world study, the frequency of detectable HCV RNA in EOT was 7% for 471 patients. In addition, 3% of the patients even had quantifiable viral load at the EOT. When highly sensitive HCV RNA assays are used, detectable and even quantifiable results of HCV RNA are quite common. As SVR rates remain high in these patients, treatment prolongation was not indicated.